Aminocaproic acid competitively inhibits the binding of plasminogen to fibrin, preventing its activation and thereby suppressing fibrinolysis. At high concentrations (100 mg/L), it directly inhibits plasmin activity to achieve hemostasis. It is indicated for the prevention and treatment of hemorrhage caused by hyperfibrinolysis.
GMP、DMF
